WO2022231298A1 - 신규한 항-cd5 키메릭 항원 수용체 및 이를 발현하는 면역세포 - Google Patents
신규한 항-cd5 키메릭 항원 수용체 및 이를 발현하는 면역세포 Download PDFInfo
- Publication number
- WO2022231298A1 WO2022231298A1 PCT/KR2022/006009 KR2022006009W WO2022231298A1 WO 2022231298 A1 WO2022231298 A1 WO 2022231298A1 KR 2022006009 W KR2022006009 W KR 2022006009W WO 2022231298 A1 WO2022231298 A1 WO 2022231298A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- cells
- amino acid
- acid sequence
- car
- Prior art date
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 title claims abstract description 113
- 210000002865 immune cell Anatomy 0.000 title claims abstract description 67
- 101000934341 Homo sapiens T-cell surface glycoprotein CD5 Proteins 0.000 claims abstract description 167
- 102100025244 T-cell surface glycoprotein CD5 Human genes 0.000 claims abstract description 167
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 36
- 210000004027 cell Anatomy 0.000 claims description 283
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 89
- 206010028980 Neoplasm Diseases 0.000 claims description 87
- 201000011510 cancer Diseases 0.000 claims description 80
- 239000000427 antigen Substances 0.000 claims description 73
- 102000036639 antigens Human genes 0.000 claims description 73
- 108091007433 antigens Proteins 0.000 claims description 73
- 230000027455 binding Effects 0.000 claims description 69
- 210000000822 natural killer cell Anatomy 0.000 claims description 63
- 239000012634 fragment Substances 0.000 claims description 43
- 238000000034 method Methods 0.000 claims description 29
- 108091033319 polynucleotide Proteins 0.000 claims description 25
- 102000040430 polynucleotide Human genes 0.000 claims description 25
- 239000002157 polynucleotide Substances 0.000 claims description 25
- 230000004068 intracellular signaling Effects 0.000 claims description 24
- 239000013604 expression vector Substances 0.000 claims description 21
- 239000008194 pharmaceutical composition Substances 0.000 claims description 21
- 239000002773 nucleotide Substances 0.000 claims description 15
- 125000003729 nucleotide group Chemical group 0.000 claims description 15
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 8
- 206010025323 Lymphomas Diseases 0.000 claims description 8
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 6
- 210000000581 natural killer T-cell Anatomy 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 5
- 239000002246 antineoplastic agent Substances 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- 230000001093 anti-cancer Effects 0.000 claims description 4
- 210000002540 macrophage Anatomy 0.000 claims description 4
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 3
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 3
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims description 3
- 208000027190 Peripheral T-cell lymphomas Diseases 0.000 claims description 3
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 3
- 208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 claims description 3
- 201000009365 Thymic carcinoma Diseases 0.000 claims description 3
- 230000001154 acute effect Effects 0.000 claims description 3
- 230000001684 chronic effect Effects 0.000 claims description 3
- 210000004443 dendritic cell Anatomy 0.000 claims description 3
- 201000005787 hematologic cancer Diseases 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 201000011649 lymphoblastic lymphoma Diseases 0.000 claims description 3
- 208000020968 mature T-cell and NK-cell non-Hodgkin lymphoma Diseases 0.000 claims description 3
- 208000008732 thymoma Diseases 0.000 claims description 3
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 230000002829 reductive effect Effects 0.000 abstract description 15
- 230000001988 toxicity Effects 0.000 abstract description 5
- 231100000419 toxicity Toxicity 0.000 abstract description 5
- 229940123776 Immuno-oncology therapy Drugs 0.000 abstract 1
- 230000003013 cytotoxicity Effects 0.000 description 54
- 231100000135 cytotoxicity Toxicity 0.000 description 54
- 230000000694 effects Effects 0.000 description 30
- 108090000623 proteins and genes Proteins 0.000 description 30
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 23
- 230000001461 cytolytic effect Effects 0.000 description 18
- 235000001014 amino acid Nutrition 0.000 description 16
- 108090000695 Cytokines Proteins 0.000 description 14
- 102000004127 Cytokines Human genes 0.000 description 14
- 150000001413 amino acids Chemical class 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 14
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 14
- 230000011664 signaling Effects 0.000 description 14
- 210000005087 mononuclear cell Anatomy 0.000 description 13
- 230000028327 secretion Effects 0.000 description 11
- 239000003446 ligand Substances 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 9
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 9
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 9
- 108020004999 messenger RNA Proteins 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 108090000765 processed proteins & peptides Proteins 0.000 description 9
- 230000004913 activation Effects 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 108060003951 Immunoglobulin Proteins 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 102000018358 immunoglobulin Human genes 0.000 description 7
- 229950010131 puromycin Drugs 0.000 description 7
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 6
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 6
- 241000282414 Homo sapiens Species 0.000 description 6
- 108091008874 T cell receptors Proteins 0.000 description 6
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 6
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 6
- -1 at least 12 Chemical class 0.000 description 6
- 238000012790 confirmation Methods 0.000 description 6
- 238000013518 transcription Methods 0.000 description 6
- 230000035897 transcription Effects 0.000 description 6
- 239000013603 viral vector Substances 0.000 description 6
- 102100029360 Hematopoietic cell signal transducer Human genes 0.000 description 5
- 101000990188 Homo sapiens Hematopoietic cell signal transducer Proteins 0.000 description 5
- 241000713666 Lentivirus Species 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000000139 costimulatory effect Effects 0.000 description 5
- 238000000684 flow cytometry Methods 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 4
- 108010076504 Protein Sorting Signals Proteins 0.000 description 4
- 238000002659 cell therapy Methods 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- 231100000433 cytotoxic Toxicity 0.000 description 4
- 230000001472 cytotoxic effect Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 210000004700 fetal blood Anatomy 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 230000019491 signal transduction Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 125000006850 spacer group Chemical group 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 241000701022 Cytomegalovirus Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 3
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 description 3
- 102100037850 Interferon gamma Human genes 0.000 description 3
- 108010074328 Interferon-gamma Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 description 3
- 230000000735 allogeneic effect Effects 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 229940041181 antineoplastic drug Drugs 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- DEGAKNSWVGKMLS-UHFFFAOYSA-N calcein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(O)=O)CC(O)=O)=C(O)C=C1OC1=C2C=C(CN(CC(O)=O)CC(=O)O)C(O)=C1 DEGAKNSWVGKMLS-UHFFFAOYSA-N 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 3
- 210000004405 cytokine-induced killer cell Anatomy 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 229960002378 oftasceine Drugs 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000009870 specific binding Effects 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 238000010361 transduction Methods 0.000 description 3
- 230000026683 transduction Effects 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 3
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 102100025466 Carcinoembryonic antigen-related cell adhesion molecule 3 Human genes 0.000 description 2
- 206010057248 Cell death Diseases 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 description 2
- 101000914337 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 3 Proteins 0.000 description 2
- 101001023379 Homo sapiens Lysosome-associated membrane glycoprotein 1 Proteins 0.000 description 2
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 102100025390 Integrin beta-2 Human genes 0.000 description 2
- 108010065805 Interleukin-12 Proteins 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 102100035133 Lysosome-associated membrane glycoprotein 1 Human genes 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 2
- 102100027208 T-cell antigen CD7 Human genes 0.000 description 2
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 2
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 2
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- BQRGNLJZBFXNCZ-UHFFFAOYSA-N calcein am Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)=C(OC(C)=O)C=C1OC1=C2C=C(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(=O)C)C(OC(C)=O)=C1 BQRGNLJZBFXNCZ-UHFFFAOYSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 229960004679 doxorubicin Drugs 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 2
- 208000024908 graft versus host disease Diseases 0.000 description 2
- 230000005931 immune cell recruitment Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 230000000527 lymphocytic effect Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000011987 methylation Effects 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- 238000007500 overflow downdraw method Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
- 229960004618 prednisone Drugs 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000003151 transfection method Methods 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
- 229960004528 vincristine Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- ZVEUWSJUXREOBK-DKWTVANSSA-N 2-aminoacetic acid;(2s)-2-amino-3-hydroxypropanoic acid Chemical group NCC(O)=O.OC[C@H](N)C(O)=O ZVEUWSJUXREOBK-DKWTVANSSA-N 0.000 description 1
- 102100023990 60S ribosomal protein L17 Human genes 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 108010031480 Artificial Receptors Proteins 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 241000193388 Bacillus thuringiensis Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102100036842 C-C motif chemokine 19 Human genes 0.000 description 1
- 102100027207 CD27 antigen Human genes 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 102100035793 CD83 antigen Human genes 0.000 description 1
- 102100037904 CD9 antigen Human genes 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 description 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102100030340 Ephrin type-A receptor 2 Human genes 0.000 description 1
- 101710116743 Ephrin type-A receptor 2 Proteins 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 108091092584 GDNA Proteins 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 1
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000713106 Homo sapiens C-C motif chemokine 19 Proteins 0.000 description 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 1
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 1
- 101000738354 Homo sapiens CD9 antigen Proteins 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 1
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 1
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 description 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 101000914496 Homo sapiens T-cell antigen CD7 Proteins 0.000 description 1
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 description 1
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 description 1
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 1
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 101000809875 Homo sapiens TYRO protein tyrosine kinase-binding protein Proteins 0.000 description 1
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 description 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 102000012214 Immunoproteins Human genes 0.000 description 1
- 108010036650 Immunoproteins Proteins 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 description 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 1
- 206010052178 Lymphocytic lymphoma Diseases 0.000 description 1
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101100370002 Mus musculus Tnfsf14 gene Proteins 0.000 description 1
- 102000010168 Myeloid Differentiation Factor 88 Human genes 0.000 description 1
- 108010077432 Myeloid Differentiation Factor 88 Proteins 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 description 1
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- 102100038717 TYRO protein tyrosine kinase-binding protein Human genes 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- PVNJLUVGTFULAE-UHFFFAOYSA-N [NH4+].[Cl-].[K] Chemical compound [NH4+].[Cl-].[K] PVNJLUVGTFULAE-UHFFFAOYSA-N 0.000 description 1
- SAZUGELZHZOXHB-UHFFFAOYSA-N acecarbromal Chemical compound CCC(Br)(CC)C(=O)NC(=O)NC(C)=O SAZUGELZHZOXHB-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229940097012 bacillus thuringiensis Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229960003669 carbenicillin Drugs 0.000 description 1
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000006126 farnesylation Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000003197 gene knockdown Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 102000002467 interleukin receptors Human genes 0.000 description 1
- 108010093036 interleukin receptors Proteins 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 101150079601 recA gene Proteins 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 230000019635 sulfation Effects 0.000 description 1
- 238000005670 sulfation reaction Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4613—Natural-killer cells [NK or NK-T]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464429—Molecules with a "CD" designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the structure of the chimeric antigen receptor [CAR]
- A61K2239/23—On/off switch
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Definitions
- the present invention relates to a novel antibody or antigen-binding fragment thereof that specifically binds to CD5, a chimeric antigen receptor comprising the antigen-binding fragment of the antibody, and an immune cell expressing the chimeric antigen receptor.
- TIL tumor infiltrating lymphocytes
- CAR Chimeric antigen receptor
- TCR T-cell receptor
- the CD5 is a kind of differentiation cluster expressed in T cells and B cells, is mainly found in bone marrow or lymphoid tissues, and is mainly used as a marker of T cells because it is overexpressed in T cells rather than B cells.
- CD5 since CD5 is expressed not only in most T cell tumors but also in normal T cells, anti-CD5 CAR-T cells attack not only T cell tumors but also normal T cells, or even inject anti-CD5 CAR- There was a problem of self-cross-reaction, which also attacks the T cell itself (Ref. 1). As a result, there is a problem in that normal T cells and anti-CD5 CAR-T cells are reduced, and eventually even the anticancer effect is reduced.
- Patent Document 1 Korean Patent Publication No. 2018-0002604
- Patent Document 2 Korean Patent Publication No. 2,122,546
- An object of the present invention is to provide an antibody or antigen-binding fragment thereof capable of specifically binding to CD5.
- Another object of the present invention is to provide a novel chimeric antigen receptor capable of amplifying cytotoxic or cytolytic activity against cancer cells when expressed in immune cells.
- Another object of the present invention is to provide a polynucleotide and an expression vector for expressing the chimeric antigen receptor.
- Another object of the present invention is to provide immune cells having excellent therapeutic effects on cancer by expressing the chimeric antigen receptor on the surface.
- Another object of the present invention is to provide a pharmaceutical composition for treating cancer using the immune cells.
- one aspect of the present invention is i) a heavy chain CDR1 having any one amino acid sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 10, SEQ ID NO: 18 and SEQ ID NO: 26, ii) SEQ ID NO: 3, a heavy chain CDR2 having any one amino acid sequence selected from the group consisting of SEQ ID NO: 11, SEQ ID NO: 19 and SEQ ID NO: 27, and iii) from the group consisting of SEQ ID NO: 4, SEQ ID NO: 12, SEQ ID NO: 20 and SEQ ID NO: 28 a heavy chain variable region comprising a heavy chain CDR3 having any one selected amino acid sequence; And iv) a light chain CDR1 having any one amino acid sequence selected from the group consisting of SEQ ID NO: 6, SEQ ID NO: 14, SEQ ID NO: 22 and SEQ ID NO: 30, v) SEQ ID NO: 7, SEQ ID NO: 15, SEQ ID NO: 23 and SEQ ID NO: A light chain CDR2
- the heavy chain variable region may be any one selected from the group consisting of SEQ ID NO: 5, SEQ ID NO: 13, SEQ ID NO: 21 and SEQ ID NO: 29.
- the light chain variable region may be any one selected from the group consisting of SEQ ID NO: 9, SEQ ID NO: 17, SEQ ID NO: 25 and SEQ ID NO: 33.
- Another aspect of the present invention is an extracellular domain comprising an antigen binding site that specifically binds to CD5 (extracellular binding domain); transmembrane domain; and an intracellular signaling domain; a chimeric antigen receptor (CAR), wherein the antigen binding site specifically binding to CD5 is i) SEQ ID NO: 2, SEQ ID NO: Heavy chain CDR1 having any one amino acid sequence selected from the group consisting of 10, SEQ ID NO: 18 and SEQ ID NO: 26, ii) any one selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 11, SEQ ID NO: 19 and SEQ ID NO: 27 iv) a heavy chain variable region comprising a heavy chain CDR2 having an amino acid sequence of Light chain CDR1 having any one amino acid sequence selected from the group consisting of number 6, SEQ ID NO: 14, SEQ ID NO: 22 and SEQ ID NO: 30, v) the group consisting of SEQ ID NO: 7, SEQ ID NO: 15, SEQ ID NO: 23 and SEQ ID NO: 31 A
- Another aspect of the present invention provides a polynucleotide comprising a nucleotide sequence encoding the chimeric antigen receptor, and an expression vector comprising the polynucleotide.
- the immune cells may be natural killer cells, T cells, natural killer T cells, cytokine-induced killer cells, macrophages, or dendritic cells. Another aspect of the present invention is to prevent cancer or A therapeutic pharmaceutical composition is provided.
- the cancer may be a hematologic cancer including leukemia or lymphoma, and the cancer is thymic carcinoma, non-Hodgkin lymphoma, diffuse large cell lymphoma, small lymphocytic cell lymphoma. lymphocytic lymphoma, T-cell neoplasma, peripheral T-cell lymphoma, mantle cell lymphoma, T-cell acute lymphobalstic lymphoma ) or chronic lymphoblastic lymphoma.
- the antibody, antigen-binding fragment thereof, and chimeric antigen receptor using the same of the present invention can specifically bind to CD5 expressed in cancer cells, and thus signal transduction in immune cells expressing the chimeric antigen receptor As it occurs, it significantly improves the cytotoxicity or cytolytic activity of immune cells and has the effect of promoting the secretion of cytokines. In addition, there is an effect of increasing the degranulation of cancer cells co-cultured with the immune cells, and in the case of immune cells expressing the chimeric antigen receptor, the reactivity is reduced with respect to normal cells expressing CD5. indicates
- the antibody of the present invention or a chimeric antigen receptor comprising the same, and immune cells expressing the same can be used for treating cancer.
- CD5-CAR chimeric antigen receptor
- ScFv single chain variable fragment
- CD5#1-CAR-NK cell CD5#4-CAR-NK cell, CD5#11-CAR-NK cell and CD5#14-CAR-NK cells
- CD5#1-CAR, CD5#4-CAR, CD5#11-CAR and CD5#14-CAR-NK cells the expression of the chimeric antigen receptors (CD5#1-CAR, CD5#4-CAR, CD5#11-CAR and CD5#14-CAR) of the present invention was confirmed. the results are shown.
- CD5#1-CAR-NK cells shows natural killer cells (CD5#1-CAR-NK cells, CD5#4-CAR-NK cells, CD5#11-CAR-NK cells and CD5#14-CAR-NK cells), the cytotoxicity (cytolytic activity) of MOLT4 cells expressing CD5 and U937 cells not expressing CD5 was measured and compared.
- CD5#11-CAR-NK cells and CD5#14-CAR-NK cells are natural killer cells into which the genes of the chimeric antigen receptors CD5#11-CAR and CD5#14-CAR of the present invention were introduced and expressed. of, shows the results of measuring and comparing the cytotoxicity (cytolytic activity) to CCRF-CEM cells expressing CD5 and Jurkat cells and Daudi cells not expressing CD5.
- 5A and 5B to 5E show natural killer cells (CD5#1-CAR-NK cells, CD5#4-CAR-NK cells, CD5#11) into which four genes of the chimeric antigen receptor of the present invention were introduced and expressed.
- -CAR-NK cells and CD5#14-CAR-NK cells secreted by natural killer cells (IFN- ⁇ ) when co-cultured with MOLT4 cells expressing CD5 or U937 cells not expressing CD5
- IFN- ⁇ natural killer cells
- Figure 6 shows natural killer cells (CD5#11-CAR-NK cells and CD5#14-CAR-NK cells) into which the genes of the chimeric antigen receptors CD5#11-CAR and CD5#14-CAR of the present invention were introduced and expressed. of, shows the results of measuring and comparing the cytotoxicity (cytolytic activity) to MNC (mononuclear cells) including normal cells expressing CD5.
- cytotoxicity cytolytic activity
- Figure 7a shows the chimeric antigen receptors CD5#11-CAR and CD5#14-CAR genes of the present invention introduced and expressed in natural killer cells (CD5#11-CAR-NK cells and CD5#14-CAR-NK cells) It shows the results of confirming the expression level of CD5-CAR in single cell lines in which they were isolated and propagated into single cells, and FIG. 7b shows the cytotoxicity (cytolytic activity) of each of the established single cell lines to MOLT4 cells and MNCs. to show the comparison results, and FIG. 7c shows the process of selecting a leader cell line from among the single cell lines established as described above.
- FIG. 8 is a schematic diagram showing the structure of an mRNA construct designed to transiently express the chimeric antigen receptor (CD5-CAR) of the present invention.
- Figure 11a is the result of confirming the expression level of ligands involved in the activation of natural killer cells in normal cells and cancer cell lines expressing CD5
- Figure 11b is the expression level of B7-H6 for each leukocyte using MNC The measurement results are shown.
- FIG. 12 shows the CD5#11-CAR-NK of the present invention for the cancer cell lines when the expression of B7-H6 was knocked down in MOLT4 cells and Jurkat cells, which are cancer cell lines expressing CD5. It is the result of confirming the change of cytotoxicity of cells.
- FIG. 13 shows the results of measuring the expression levels of B7-H6 and CD5 over time after the CD5#11-CARNK cells of the present invention were treated in MOLT4 and MNC, which are cancer cell lines expressing CD5.
- Novel anti-CD5 antibody, antigen-binding fragment thereof, and chimeric antigen receptor (CAR) comprising same, polynucleotide and expression vector for expressing the same
- One aspect of the present invention provides an anti-CD5 antibody and antigen-binding fragment thereof capable of specifically binding to CD5.
- the term “antibody” refers to an immunoglobulin molecule having reactivity by specific binding to an epitope of an antigen immunologically.
- the antibody may include a monoclonal antibody, a polyclonal antibody, an antibody having a full-length chain structure (full-length antibody), a functional fragment having at least an antigen-binding function (antigen-binding fragment), and a recombinant antibody.
- the antibody of the present invention may be a monoclonal antibody or an antigen-binding fragment thereof.
- the monoclonal antibody refers to an antibody molecule of a single molecular composition obtained from a population of substantially identical antibodies, and the monoclonal antibody exhibits a single binding specificity and affinity for a specific epitope.
- the full-length antibody has a structure having two full-length light chains and two full-length heavy chains, and each light chain may be linked to a heavy chain by a disulfide bond.
- the antibody includes a heavy chain (HC) and light chain (LC) polypeptide, and the heavy chain and light chain may include a variable region and a constant region.
- the constant region is a region mediating the binding of the antibody to various types of cells of the immune system (such as T-cells), host tissues including components of the complement system, and the like. If the constant region is the same type of antibody derived from the same species, it functions the same regardless of the type of antigen, and the amino acid sequence constituting it also has the same or high similarity for each antibody.
- the constant region may be divided into a heavy chain constant region (which may be abbreviated as CH) and a light chain constant region (which may be abbreviated as CL).
- the heavy chain constant region has a gamma ( ⁇ ), mu ( ⁇ ), alpha ( ⁇ ), delta ( ⁇ ) and / or epsilon ( ⁇ ) type, and subclasses gamma 1 ( ⁇ 1), gamma 2 ( ⁇ 2), gamma3 ( ⁇ 3), gamma 4 ( ⁇ 4), alpha1 ( ⁇ 1) and/or alpha2 ( ⁇ 2).
- the light chain constant region has kappa ( ⁇ ) and lambda ( ⁇ ) types.
- IgG is a subtype and includes IgG1, IgG2, IgG3 and IgG4.
- variable region is an antigen-specific antibody region, and may be divided into a heavy chain variable region (which may be abbreviated as VH) and a light chain variable region (which may be abbreviated as VL).
- the variable region may include three CDRs (complementary-determining regions, or complementarity determining regions) and four FRs (framework regions).
- the CDR may be a ring-shaped region involved in antigen recognition, and specificity for the antigen may be determined according to the amino acid sequence of the CDR.
- the CDRs may be referred to as CDR1, CDR2, or CDR3 according to their order, and depending on whether the CDR of any polypeptide of the heavy chain and light chain is CDR-H1, CDR-H2, CDR-H3 in the case of a heavy chain variable region, In the case of a light chain variable region, it may be referred to as CDR-L1, CDR-L2, CDR-L3.
- FR can be referred to as FR-H1, FR-H2, FR-H3, FR-H4 in the case of a heavy chain variable region, and FR-L1, FR-L2, FR-L3, FR-L4 in the case of a light chain variable region. have.
- the CDRs and FRs may be arranged in the following order in each variable region.
- antigen-binding fragment refers to any fragment of a humanized antibody of the present invention that retains the antigen-binding function of the antibody.
- the antigen-binding fragment may be referred to interchangeably with terms such as “fragment” and "antibody fragment”, and the antigen-binding fragment may be Fab, Fab', F(ab') 2 , Fv, etc., but is not limited thereto. .
- the Fab has a structure having a light chain and heavy chain variable regions, a light chain constant region and a first constant region (CH1 domain) of the heavy chain, and has one antigen-binding site.
- the Fab' is different from the Fab in that it has a hinge region including one or more cysteine residues at the C terminus of the heavy chain CH1 domain.
- the F(ab') 2 is generated when a cysteine residue in the hinge region of Fab' forms a disulfide bond.
- the Fv refers to a minimal antibody fragment having only a heavy chain variable region and a light chain variable region.
- the heavy chain variable region and the light chain variable region are connected by a non-covalent bond
- the heavy chain variable region and the light chain variable region are generally covalently bonded through a peptide linker. or directly linked at the C-terminus to form a dimer-like structure like a double-stranded Fv.
- the antigen-binding fragment can be prepared by using a proteolytic enzyme (for example, by restriction digestion of the whole antibody with papain, Fab can be obtained, and when digested with pepsin, a F(ab')2 fragment can be obtained), or It may be produced through genetic recombination technology, but is not limited thereto.
- a proteolytic enzyme for example, by restriction digestion of the whole antibody with papain, Fab can be obtained, and when digested with pepsin, a F(ab')2 fragment can be obtained
- It may be produced through genetic recombination technology, but is not limited thereto.
- the linker may be a peptide linker, and may have a length of about 10 to 25 amino acids.
- the linker may include a hydrophilic amino acid such as glycine (G) and/or serine (S).
- the linker may include, for example, (GS)n, (GGS)n, (GSGGS)n or (GnS)m (n and m are each 1 to 10), for example, (GnS)m( Each of n and m may be 1 to 10), but is not limited thereto.
- epitope refers to a specific site on an antigen that can be specifically recognized and bound to an immunoglobulin, an antibody, or an antigen-binding fragment thereof.
- the epitope may be formed from contiguous amino acids or from discontinuous amino acids juxtaposed by tertiary folding of the protein.
- the "specifically binds" may refer to binding to another molecule with a binding affinity greater than background binding, for example, the extracellular domain has an affinity for a target antigen of about 10 -5 M or greater or a Ka (equilibrium dissociation constant of a specific binding interaction with units of 1/M) may be binding to the target antigen.
- the affinity may be such that the equilibrium dissociation constant (Kd) of a specific binding interaction with units of M is 10 -5 M to 10 -13 M or less than or equal to the above range.
- the antibody or antigen-binding fragment thereof of the present invention is i) a heavy chain CDR1 having any one amino acid sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 10, SEQ ID NO: 18 and SEQ ID NO: 26, ii) SEQ ID NO: 3, Heavy chain CDR2 having any one amino acid sequence selected from the group consisting of SEQ ID NO: 11, SEQ ID NO: 19 and SEQ ID NO: 27, and iii) selected from the group consisting of SEQ ID NO: 4, SEQ ID NO: 12, SEQ ID NO: 20 and SEQ ID NO: 28 a heavy chain variable region comprising a heavy chain CDR3 having any one amino acid sequence; And iv) a light chain CDR1 having any one amino acid sequence selected from the group consisting of SEQ ID NO: 6, SEQ ID NO: 14, SEQ ID NO: 22 and SEQ ID NO: 30, v) SEQ ID NO: 7, SEQ ID NO: 15, SEQ ID NO: 23 and SEQ ID NO: A light chain CDR2 having
- the heavy chain variable region may have the amino acid sequence of SEQ ID NO: 5, SEQ ID NO: 13, SEQ ID NO: 21 or SEQ ID NO: 29.
- the light chain variable region may have the amino acid sequence of SEQ ID NO: 9, SEQ ID NO: 17, SEQ ID NO: 25 or SEQ ID NO: 33.
- the light chain variable region may have the amino acid sequence of SEQ ID NO: 8 or SEQ ID NO: 16.
- the antibody or antigen-binding fragment thereof of the present invention may further include a heavy chain constant region and/or a light chain constant region of, for example, a human-derived antibody, wherein the antibody or antigen-binding fragment thereof specifically binds to CD5.
- the heavy chain constant region and/or the light chain constant region of the human-derived antibody may be used without limitation on its type or amino acid sequence, as long as the properties are not impaired.
- amino acid sequences described above may include variants having different sequences by deletion, insertion, substitution, or a combination of amino acid residues within the range that does not affect the structure, function, activity, etc. of the polypeptide comprising the same.
- amino acid sequences may include amino acids that have undergone conventional modifications known in the art, and the amino acid modifications are, for example, phosphorylation, sulfation, acrylation, glycosylation, methylation ( methylation), farnesylation, and the like.
- the humanized antibody or antigen-binding fragment thereof of the present invention includes not only the amino acid sequences described above, but also those having substantially the same amino acid sequence or variants thereof.
- the meaning of having the substantially identical amino acid sequence is 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more as the amino acid sequence described above. % or more, 99% or more, or may include an amino acid sequence having homology of 99.5% or more, but is not limited thereto.
- chimeric antigen receptor is a synthetic complex designed to induce an immune response against a target antigen and a cell expressing the antigen when it is recognized and bound.
- a chimeric antigen receptor may include an extracellular binding domain, a transmembrane domain, and an intracellular signaling domain.
- the chimeric antigen receptor is expressed on the surface of immune cells and binds to a specific antigen, such as an antigen specifically expressed on the surface of a cancer cell, through an antigen binding site contained in the extracellular domain, thereby signaling within the immune cell. Since it can change the activity of immune cells by causing delivery, it is possible to induce an immune response by targeting only a specific antigen.
- the chimeric antigen receptor (CAR) of the present invention includes an extracellular binding domain comprising an antigen binding site that specifically binds to CD5 (ephrin type-A receptor 2); transmembrane domain; and an intracellular signaling domain.
- CD5 ephrin type-A receptor 2
- transmembrane domain ephrin type-A receptor 2
- intracellular signaling domain ephrin type-A receptor 2
- the antigen binding site specifically binding to CD5 is, i) a heavy chain CDR1 having any one amino acid sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 10, SEQ ID NO: 18 and SEQ ID NO: 26, ii) SEQ ID NO: 3, a heavy chain CDR2 having any one amino acid sequence selected from the group consisting of SEQ ID NO: 11, SEQ ID NO: 19 and SEQ ID NO: 27, and iii) from the group consisting of SEQ ID NO: 4, SEQ ID NO: 12, SEQ ID NO: 20 and SEQ ID NO: 28
- a heavy chain variable region comprising a heavy chain CDR3 having any one selected amino acid sequence and iv) a light chain CDR1 having any one amino acid sequence selected from the group consisting of SEQ ID NO: 6, SEQ ID NO: 14, SEQ ID NO: 22 and SEQ ID NO: 30 , v) a light chain CDR2 having any one amino acid sequence selected from the group consisting of SEQ ID NO: 7, SEQ ID NO
- the chimeric antigen receptor of the present invention When the chimeric antigen receptor of the present invention is expressed on the surface of an immune cell, when CD5, a target antigen, binds to the receptor, a signal transduction occurs within the immune cell, and the cytotoxicity (or cytolysis) of the immune cell occurs. activity) and/or promotion of cytokine secretion of the immune cells may be induced.
- the improvement of the cytotoxicity (or cytolytic activity) or the promotion of cytokine secretion is cytotoxicity (or cytolysis) at a higher level than the cytotoxicity (or cytolytic activity) or cytokine secretion exhibited by immune cells in the absence of antigen. activity) or secreting cytokines at high levels.
- the extracellular domain may further include at least one selected from the group consisting of a hinge domain and a spacer domain.
- the antigen binding site of the extracellular domain may be linked to the transmembrane domain via a hinge domain and/or a spacer domain.
- the hinge domain is, to enable proper cell/cell contact, binding of an appropriate antigen/antigen binding site, and activation of an appropriate chimeric antigen receptor, the antigen binding site from the surface of an immune cell expressing the chimeric antigen receptor. As a part that allows physically spaced apart, it may play an important role in the positioning of the extracellular domain.
- the chimeric antigen receptor may comprise one or more hinge domains between the extracellular domain and the transmembrane domain.
- the hinge domain may be derived from natural, synthetic, semi-synthetic or recombinant sources.
- the hinge domain may comprise the amino acid sequence of a naturally occurring immunoglobulin hinge region or an altered immunoglobulin hinge region.
- the altered hinge region comprises (a) a naturally occurring hinge region having at most 30% amino acid change (eg, at most 25%, 20%, 15%, 10% or 5% amino acid substitutions or deletions), (b) at most 30 a native of at least 10 amino acids (e.g., at least 12, 13, 14 or 15 amino acids) in length with % amino acid change (e.g., amino acid substitutions or deletions of up to 25%, 20%, 15%, 10% or 5%) part of a developing hinge region, or (c) a core hinge region, which is 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15, or at least 4, 5, 6, 7, 8 , 9, 10, 11, 12, 13, 14 or 15 amino acids in length).
- one or more cysteine residues in the naturally occurring immunoglobulin hinge region may be substituted with one or more other amino acid residues (eg, one or more serine residues).
- the altered immunoglobulin hinge region may alternatively or additionally have a proline residue of the wild-type immunoglobulin hinge region substituted with another amino acid residue, such as cysteine.
- the hinge domain may be a hinge region derived from the extracellular domain of a type 1 membrane protein such as CD8, CD4, CD28 and CD7, but if it is capable of connecting the antigen-binding site, the transmembrane domain, and the intracellular signaling domain between the cell membranes Any of them may be used without limitation. It can also be a wild-type hinge region from these molecules or it can be changed.
- the spacer domain may be referred to as a linking domain, for example, it may include a hinge domain derived from CD28 and/or a hinge domain derived from CD8, and the entire or It may include some.
- the hinge domain and/or spacer domain may be at least one selected from the group consisting of Myc epitope, CD8 hinge domain, and Fc, and specifically may include Myc epitope and CD8 hinge domain.
- the transmembrane domain refers to a partial region that connects and fuses the extracellular domain and the intracellular signaling domain with each other and serves to fix the chimeric antigen receptor to the plasma membrane of an immune cell.
- the transmembrane domain may be derived from a natural, synthetic, semi-synthetic or recombinant source.
- the transmembrane domain is the alpha ( ⁇ ), beta ( ⁇ ) or zeta ( ⁇ ) chain of T-cell receptor (TCR), CD28, CD3 epsilon ( ⁇ ), CD45, CD4, CD5, CD8, CD9, CD16, CD22 , CD33, CD37, CD64, CD80, CD86, CD134, CD137 and CD154 may be any one selected from the group consisting of, but is not limited thereto.
- the transmembrane domain may be attached to the extracellular domain via a linker.
- the linker may be a short oligopeptide or polypeptide linker of 2 to 10 amino acids in length, such as, but not limited to, a glycine (G)-serine (S) doublet.
- the intracellular signaling domain is an immune cell function (eg, activation, including release of a cytotoxic (or cytolytic activity) factor to a target cell to which the chimeric antigen receptor and antigen are bound, cytokine production, To induce proliferation and cytotoxic or cytolytic activity, or other cellular responses induced by the antigen binding) corresponds to the part.
- the intracellular signaling domain may be part of a protein that transmits an operative function signal and directs the cell to perform a specific function.
- an intracellular signaling domain previously used in the development of a chimeric antigen receptor may be used. Specifically, it may include only CD3 ⁇ , which was used in the first generation CAR (chimeric antigen receptor). And, as used in the second-generation CAR, a form in which a costimulatory domain (CD28 or CD137/4-1BB) and CD3 ⁇ are combined can be used to improve responsiveness to immune cells. In addition, two or more co-stimulatory domains can be used as used in the third-generation CAR, and in this case, the co-stimulatory domain is 4-1BB, CD28 or OX40, etc. can be combined.
- the CAR-based immunoprotein of the cytokine can be further expressed, and the 5th generation CAR
- an interleukin receptor chain for example, IL-2R ⁇ , may be further included to enhance immune cells.
- the intracellular signaling domain includes T-cell receptor (TCR) zeta ( ⁇ ), FcR gamma ( ⁇ ), FcR beta ( ⁇ ), CD3 gamma ( ⁇ ), CD3 delta ( ⁇ ), CD3 epsilon ( ⁇ ), CD3 It may include at least one selected from the group consisting of zeta ( ⁇ ), CD5, CD22, CD79a, CD79b, and CD66d.
- activation of the immune cell by the intracellular signaling domain may be mediated by two different classes of intracellular signaling domains.
- immune cell activation can be mediated by a primary signaling domain that initiates antigen-dependent primary activation and a costimulatory signaling domain that acts in an antigen-independent manner to provide a secondary signal.
- the intracellular signaling domain may include a primary signaling domain and a co-stimulatory signaling domain.
- the primary signaling domain refers to a signaling domain that regulates immune cell activation in a stimulating or inhibitory manner.
- a primary signaling domain that acts in a stimulatory manner may contain a signaling motif known as an immunoreceptor tyrosine-based activation motif or ITAM.
- ITAM containing the primary signaling domain may be, but is not limited to, TCR ⁇ , FcR ⁇ , FcR ⁇ , CD3 ⁇ , CD3 ⁇ , CD3 ⁇ , CD5, CD22, CD79a, CD79b, CD66d, and the like. More specifically, the primary signaling domain may be CD3 ⁇ (zeta), but is not limited thereto.
- the co-stimulatory signaling domain refers to an intracellular signaling domain of a co-stimulatory molecule.
- the costimulatory signaling domains are CD2, CD7, CD27, CD28, CD30, CD40, 4-1BB (CD137), OX40 (CD134), CDS, ICAM-1, ICOS (CD278), LFA-1 (CD11a/CD18) , GITR, MyD88, DAP10, DAP12, PD-1, LIGHT, NKG2C, CD5, CD83, and the like may include a co-stimulatory signaling domain selected from the group consisting of, but is not limited thereto. .
- the costimulatory molecule may be DAP10, but is not limited thereto.
- the chimeric antigen receptor may include two or more intracellular signaling domains, and when it includes two or more intracellular signaling domains, the intracellular signaling domains may be connected in series with each other. Alternatively, it may be linked through a polypeptide linker consisting of 2 to 10 amino acids, and the linker sequence may be, for example, a glycine-serine sequence.
- the linker may include, for example, (GS)n, (GGS)n, (GSGGS)n or (GnS)m (n and m are each 1 to 10), for example, (GnS)m( Each of n and m may be 1 to 10), but is not limited thereto.
- the chimeric antigen receptor may further include a signal (signal) peptide for domain exposure.
- the signal (signal) peptide may be any type of secreted or transmembrane protein, which may direct the transport of the chimeric antigen receptor to the cell membrane or cell surface and provide precise localization.
- a specific type may be CD8 alpha or mouse light kappa signal peptide, but is not limited thereto.
- the chimeric antigen receptor of the present invention when expressed on the surface of immune cells to recognize and bind to CD5, it is possible to improve the cytotoxicity or cytolytic activity of immune cells or induce cytokine secretion of immune cells. can Therefore, when the antigen-binding site of the chimeric antigen receptor recognizes and binds to an antigen in the presence of cancer cells expressing CD5, the cytotoxicity or cytolytic activity of immune cells is enhanced by signal transduction and/or cytokine secretion is promoted This can be induced, so it can be usefully used as a chimeric antigen receptor with excellent cytotoxic or cytolytic efficacy against cancer cells.
- Another aspect of the present invention provides a polynucleotide and an expression vector for expressing the chimeric antigen receptor.
- the polynucleotide includes a nucleotide sequence encoding the chimeric antigen receptor.
- polynucleotide comprehensively includes DNA (gDNA and cDNA) and RNA molecules, and the basic structural unit nucleotide includes not only natural nucleotides, but also analogs in which sugar or base sites are modified. do.
- the polynucleotide of the present invention may include a nucleotide sequence encoding an antigen-binding fragment of the anti-CD5 antibody that specifically binds to CD5.
- polynucleotide of the present invention may include not only the nucleotide sequence encoding the antigen-binding fragment, but also a nucleotide sequence encoding other extracellular domain portions linked thereto, the transmembrane domain and/or the intracellular signaling domain. have.
- chimeric antigen receptor such as the antibody, the antigen-binding fragment, the extracellular domain, the transmembrane domain, and the intracellular signaling domain, is the same as those described above.
- the polynucleotide of the present invention may include a nucleotide sequence substantially identical to the nucleotide sequence listed above.
- the substantially identical nucleotide sequence includes, for example, a case in which the same amino acid can be synthesized when transcribed and translated, and is 90% or more, 91% or more, 92% or more, 93% or more, 94% or more of the nucleotide sequences listed above. It may be a nucleotide sequence having homology of at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5%, but is not limited thereto.
- the polynucleotide encoding the chimeric antigen receptor may include a nucleotide sequence optimized according to the type of organism to be introduced and expressed and the expression system such as transcription and translation of the organism. This is due to the degeneracy of codons. Accordingly, various combinations of nucleotide sequences that can encode the expressed protein may exist, all of which are included in the scope of the present invention. Modification of the polynucleotide according to the codon optimization may be determined according to the type of organism to be applied by expressing the chimeric antigen receptor of the present invention. For example, the polynucleotide of the present invention is optimized for codon selection in mammals and primates. It may be a modified polynucleotide, and more specifically, it may be modified and optimized to be suitable for expression from a human.
- the expression vector of the present invention includes the polynucleotide.
- the expression vector including the same can be used to express and prepare the chimeric antigen receptor, and the chimeric antigen receptor is It may serve to move the polynucleotide to a specific cell or organism so that it can be expressed, or it may be used to store and store the polynucleotide.
- vector is meant a DNA preparation containing a DNA sequence operably linked to suitable regulatory sequences capable of expressing the DNA in a suitable host.
- a vector can be a plasmid, a phage particle, or simply a potential genomic insert. Once transformed into an appropriate host, the vector can replicate and function independently of the host genome, or in some cases can be integrated into the genome itself.
- expression vector generally refers to a double-stranded DNA fragment as a recombinant carrier into which a heterologous DNA fragment is inserted.
- heterologous DNA refers to heterologous DNA, which is DNA not found naturally in a host cell.
- An expression vector once in the host cell, can replicate independently of the host chromosomal DNA and several copies of the vector and its inserted (heterologous) DNA can be produced.
- the expression vector can be constructed using a prokaryotic cell or a eukaryotic cell as a host.
- a strong promoter capable of propagating transcription eg, tac promoter, lac promoter, lacUV5 promoter, lpp promoter, pL ⁇ promoter, pR ⁇ promoter, rac5 promoter, amp promoter, recA promoter, SP6 promoter, trp promoter and T7 promoter, etc.
- a ribosome binding site for initiation of translation e.g., amp promoter, recA promoter, SP6 promoter, trp promoter and T7 promoter, etc.
- E. coli eg, HB101, BL21, DH5 ⁇ , etc.
- promoter and operator regions of the E eg, HB101, BL21, DH5 ⁇ , etc.
- coli tryptophan biosynthesis pathway (Yanofsky, C, J Bacteriol, (1984) 158:1018-1024)
- the left-handed promoter of phage ⁇ (pL ⁇ promoter, Herskowitz, I and Hagen, D, Ann Rev Genet, (1980) 14:399-445) can be used as regulatory regions.
- the promoter of the toxin protein gene of Bacillus thuringiensis (Appl Environ Microbiol (1998) 64:3932-3938; Mol Gen Genet (1996) 250:734-741) or expressed in Bacillus bacteria Any possible promoter can be used as a regulatory region.
- the expression vectors are plasmids often used in the art (e.g., pCL, pSC101, pGV1106, pACYC177, ColE1, pKT230, pME290, pBR322, pUC8/9, pUC6, pBD9, pHC79, pIJ61, pLAFR1, pHV14, pGEX series. , pET series and pUC19, etc.), phage (eg, ⁇ gt4 ⁇ B, ⁇ -Charon, ⁇ z1 and M13, etc.) or viruses (eg, SV40, etc.).
- plasmids often used in the art (e.g., pCL, pSC101, pGV1106, pACYC177, ColE1, pKT230, pME290, pBR322, pUC8/9, pUC6, pBD9, pHC79, pIJ61, pLAFR1, pHV14,
- a promoter derived from the genome of a mammalian cell eg, metallotionine promoter, ⁇ -actin promoter, human heglobin promoter and human muscle creatine promoter
- mammalian Promoters derived from animal viruses e.g., adenovirus late promoter, vaccinia virus 75K promoter, SV40 promoter, cytomegalovirus (CMV) promoter, tk promoter of HSV, mouse mammary tumor virus (MMTV) promoter, LTR of HIV promoter, the promoter of Moloney virus, the promoter of Epstein Barr virus (EBV) and the promoter of Loose Sacoma virus (RSV)
- the expression vector may have a CMV promoter.
- the expression vector may be fused with other sequences to facilitate purification of the antibody expressed therefrom.
- Sequences to be fused include, for example, glutathione S-transferase (Pharmacia, USA), maltose binding protein (NEB, USA), FLAG (IBI, USA) and 6x His (hexahistidine; Quiagen, USA).
- the protein expressed by the expression vector of the present invention is a chimeric antigen receptor, considering its characteristics, the expressed protein may be easily purified through a protein A column or the like without an additional sequence for purification.
- the expression vector includes an antibiotic resistance gene commonly used in the art as a selection marker, for example, ampicillin, gentamicin, carbenicillin, chloramphenicol, streptomycin, kanamycin, geneticin, neomycin and tetracycline. It may contain a resistance gene for example, ampicillin, gentamicin, carbenicillin, chloramphenicol, streptomycin, kanamycin, geneticin, neomycin and tetracycline. It may contain a resistance gene for example, ampicillin, gentamicin, carbenicillin, chloramphenicol, streptomycin, kanamycin, geneticin, neomycin and tetracycline. It may contain a resistance gene for example, ampicillin, gentamicin, carbenicillin, chloramphenicol, streptomycin, kanamycin, geneticin, neomycin and tetracycline. It may contain a resistance gene for example, ampicillin, gentamicin, carbenicillin
- the expression vector may further include a promoter that promotes the expression of a gene to be transfected and a basic element necessary for transcription, as well as an enhancer that can be used for promotion and regulation of expression.
- Another aspect of the present invention provides immune cells characterized by exhibiting enhanced cytotoxicity or cytolytic activity against cancer cells expressing CD5.
- the immune cells express the above-described chimeric antigen receptor of the present invention on their surface.
- the chimeric antigen receptor is described above in " 1. Novel anti-CD5 antibody, antigen-binding fragment thereof, and chimeric antigen comprising the same.
- the chimeric antigen receptor may include an antigen binding site capable of specifically binding to a CD5 antigen expressed in cancer cells.
- expressing the chimeric antigen receptor on the surface of an immune cell is meant any immune cell engineered by addition or modification of a nucleic acid encoding the chimeric antigen receptor. Therefore, in order to express the chimeric antigen receptor on the surface of immune cells as described above, a polynucleotide encoding the chimeric antigen receptor or an expression vector comprising the same is transfected (transfection) or transfected into the immune cells. can be introduced (transduction).
- the transfection is calcium phosphate-DNA co-precipitation method, DEAE-dextran-mediated transfection method, polybrene-mediated transfection method, electroshock method, microinjection method, liposome fusion method, lipofectamine and protoplast fusion method, etc.
- the transfection means transferring a gene into a cell using a virus or viral vector particle by means of infection.
- transfection and transduction may be used interchangeably, but it is preferable to be interpreted as transformation (transformation) of delivery of a foreign gene to a host cell in a larger sense, and a cell into which a foreign gene is introduced by transfection or transduction. are called transformants.
- the immune cells may be used without limitation as long as they are cells capable of inducing a desired therapeutic effect by inducing immunity, and may be obtained from peripheral blood, umbilical cord blood, bone marrow, tumor-infiltrating lymphocytes, lymph node tissue or thymus tissue, placental cells, It can be obtained by differentiation from embryonic stem cells, induced pluripotent stem cells or hematopoietic stem cells.
- the immune cells can be obtained from human, monkey, chimpanzee, dog, cat, mouse, rat and transgenic species thereof as well as established cell lines.
- the method for obtaining immune cells may use any means known in the art, and may be obtained from autologous, allogeneic or xenogeneic.
- Autologous means all cells derived from the same individual to be subsequently reintroduced into the individual
- allogeneic means all cells derived from another animal of the same species as the individual into which the cells are introduced
- heterologous means a cell derived from an animal of a different species.
- the immune cells are natural killer cells (Natural Killer cells, NK cells), T cells, natural killer T cells (NKT cells), cytokine-induced killer cells (CIK), macrophages , may be any one selected from dendritic cells, etc., but is not limited thereto. Therefore, the immune cells expressing the chimeric antigen receptor according to the present invention on the cell surface are CAR-NK cells (Chimeric Antigen Receptor Natural Killer Cells), CAR-T cells (Chimeric Antigen Receptor T Cells), CAR-NKT cells (Chimeric Antigen Cells). Receptor Natural killer T Cell), CAR-macrophage (Chimeric Antigen Receptor Macrophage), and the like.
- CAR-NK cells Chimeric Antigen Receptor Natural Killer Cells
- CAR-T cells Chimeric Antigen Receptor T Cells
- CAR-NKT cells Chomeric Antigen Cells
- Receptor Natural killer T Cell CAR-macrophage (Chimeric Anti
- Immune cells provided in the present invention can regulate the onset (on) / stop (off) of a response to a target cell of a conventional chimeric antigen receptor, so that subsequent cell therapy, the activity of the treated cell needs to be increased or decreased Includes safety switches which can be very beneficial in situations.
- safety switches which can be very beneficial in situations.
- immune cells expressing a chimeric antigen receptor are provided to a patient, there may be side effects, such as off-target toxicity, in some circumstances.
- the therapeutic cell may act to reduce the number or tumor size of the tumor cells and may no longer be needed. In this situation, it can be controlled so that the therapeutic cells are no longer activated.
- the CAR-NK cells in which the chimeric antigen receptor is introduced into natural killer cells, have problems due to the continuous toxicity of cancer immunotherapy when using the existing T-cell-based CAR-T therapeutics,
- the risk of immune disease, the problem of graft-versus-host disease (GVHD) for xenogeneic cell transplantation, and the problem of off-target toxicity can be solved through the switch on/off of the reaction, as well as various cancer cells. It has the advantage that it can be used as a general-purpose therapeutic agent by allowing it to be targeted.
- Immune cells of the present invention include a chimeric antigen receptor comprising an antigen-binding variable fragment (scFv) of an antibody capable of specifically recognizing and binding to CD5, which can be specifically expressed in cancer cells, as an extracellular domain, expressed on the cell surface. Therefore, when the CD5-expressing cancer cells are present, signal transduction may occur by the chimeric antigen receptor, thereby further improving the cytotoxicity or cytolytic activity of immune cells and increasing the secretion of cytokines. . Therefore, the immune cells of the present invention may have an activity of attacking and treating cancer cells.
- scFv antigen-binding variable fragment
- a chimeric antigen receptor comprising the antigen-binding variable fragments of four types of CD5-specific antibodies of the present invention as extracellular domains was expressed on the surface of natural killer cells.
- CD5-expressing cancer cell lines such as MOLT4 cells, CCRF-CEM, and Jurkat cells
- cytotoxicity or cytolytic activity
- cytokine secretion and degranulation was not only significantly increased, but also showed reduced cytotoxicity against MNCs containing normal cells expressing CD5. It was confirmed that there was a therapeutic effect.
- Another aspect of the present invention provides a pharmaceutical composition for preventing or treating cancer comprising the immune cells as an active ingredient.
- the description of the immune cells, the chimeric antigen receptor expressed therefrom, etc. is, " 1. Novel anti-CD5 antibody, antigen-binding fragment thereof, and a chimeric antigen receptor (CAR) comprising the same, and the expression thereof Polynucleotides and expression vectors for making these are the same as those described in the sections “ 2. Immune cells expressing a chimeric antigen receptor for CD5 on their surface ” and, therefore, descriptions are omitted in order to avoid repeated explanations.
- cancer is used interchangeably with “tumor”, and refers to or refers to a physiological condition in mammals that is typically characterized by unregulated cell growth/proliferation.
- the pharmaceutical composition of the present invention may include 1 to 10 times, 2 to 10 times, or 5 to 8 times the number of immune cells compared to the number of tumor cells of the subject to be treated, but limited thereto it's not going to be
- Anticancer drugs used in chemotherapy induce apoptosis of cells with active proliferation, and irradiation to increase the therapeutic effect of anticancer drugs increases such apoptosis.
- cells induced by apoptosis by anticancer agents and radiation are not limited to cancer cells, and may also affect immune cell therapy agents administered to an individual for immunotherapy.
- Chemotherapy includes, but is not limited to, CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone), EPOCH (etoposide, vincristine, doxorubicin, cyclophosphamide, prednisone), or any other multidrug therapy.
- cell therapy agent refers to cells and tissues manufactured through separation, culture, and special manipulation from an individual, and is a drug (US FDA regulation) used for the purpose of treatment, diagnosis, and prevention, restoring the function of cells or tissues. It refers to a drug used for the purpose of treatment, diagnosis, and prevention through a series of actions such as proliferating and selecting living autologous, allogeneic, or xenogeneic cells in vitro or changing the biological properties of cells in other ways.
- the pharmaceutical composition of the present invention may additionally include a pharmaceutically or pharmaceutically acceptable carrier.
- a pharmaceutically or pharmaceutically acceptable carrier is that it does not inhibit the activity of the active ingredient and does not have more toxicity than that applicable to the application (prescription) target, and the 'carrier' facilitates the addition of the compound into cells or tissues. It is defined as a compound that causes
- the pharmaceutical composition of the present invention may be administered alone or in admixture with any convenient carrier, and the dosage form may be a single administration or repeated administration.
- the pharmaceutical composition may be a solid formulation or a liquid formulation.
- Solid preparations include, but are not limited to, powders, granules, tablets, capsules, suppositories, and the like.
- Solid formulations may include, but are not limited to, carriers, flavoring agents, binders, preservatives, disintegrants, lubricants, fillers, and the like.
- Liquid formulations include, but are not limited to, solutions such as water and propylene glycol solutions, suspensions, and emulsions, and may be prepared by adding suitable colorants, flavoring agents, stabilizers, and viscosifying agents.
- the powder can be prepared by simply mixing the tri-hydroxy derivative of polyunsaturated fatty acid, which is the active ingredient of the present invention, with a suitable pharmaceutically acceptable carrier such as lactose, starch, microcrystalline cellulose.
- the granules are prepared by mixing the tri-hydroxy derivative of the polyunsaturated fatty acid of the present invention, a suitable pharmaceutically acceptable carrier and a suitable pharmaceutically acceptable binder such as polyvinylpyrrolidone and hydroxypropylcellulose, followed by water, It may be prepared using a wet granulation method using a solvent such as ethanol or isopropanol or a dry granulation method using a compression force.
- tablets may be prepared by mixing the granules with a suitable pharmaceutically acceptable lubricant such as magnesium stearate, and then tableting the granules using a tablet press.
- the pharmaceutical composition of the present invention is an oral agent, an injection (eg, intramuscular injection, intraperitoneal injection, intravenous injection, infusion, subcutaneous injection, implant), inhalant, nasal administration depending on the disease to be treated and the condition of the individual It may be administered as an oral preparation, vaginal preparation, rectal administration preparation, sublingual preparation, transdermal preparation, topical preparation, and the like, but is not limited thereto. Depending on the route of administration, it may be formulated into suitable dosage unit formulations containing commonly used, non-toxic, pharmaceutically acceptable carriers, excipients, and vehicles.
- the pharmaceutical composition of the present invention can be used through an ampoule for injection.
- the injection ampoule may be prepared by mixing with an injection solution immediately before use, and physiological saline, glucose, mannitol, Ringer's solution, etc. may be used as the injection solution.
- the pharmaceutical composition or formulation of the present invention thus prepared may be administered in the form of a mixture together with cells used for transplantation and other uses using administration methods commonly used in the art.
- the actual dosage of the active ingredient should be determined in light of several related factors such as the disease to be treated, the severity of the disease, the route of administration, and the weight, age and sex of the patient.
- the preferred dosage of the pharmaceutical composition of the present invention varies depending on the condition and weight of the patient, the degree of disease, the drug form, the route of administration, and the period, but may be appropriately selected by those skilled in the art.
- the pharmaceutical composition may be administered in a daily dose of about 0.0001 mg/kg to about 10 g/kg, and a daily dose of about 0.001 mg/kg to about 1 g/kg.
- the dosage may vary depending on the degree of purification of the mixture, the patient's condition (age, sex, weight, etc.), and the severity of the condition being treated. If necessary, for convenience, the total daily dose may be divided and administered several times during the day.
- the composition may be in the form of a quasi-drug composition, a composition for health food, etc. in addition to the pharmaceutical composition.
- another aspect of the present invention provides a method for preventing or treating cancer, comprising administering the immune cells to an individual in need of treatment.
- the immune cells may be in the form of the above-described pharmaceutical composition, and a person skilled in the art to which the present invention pertains may determine an appropriate administration route and dose of the pharmaceutical composition.
- a heavy chain comprising a heavy chain CDR1 having the amino acid sequence of SEQ ID NO: 2, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO: 3, and a heavy chain CDR3 having the amino acid sequence of SEQ ID NO: 4 It was designed to include a variable region and a light chain variable region comprising a light chain CDR1 having the amino acid sequence of SEQ ID NO: 6, a light chain CDR2 having the amino acid sequence of SEQ ID NO: 7, and a light chain CDR3 having the amino acid sequence of SEQ ID NO: 8.
- a heavy chain variable region comprising a heavy chain CDR1 having the amino acid sequence of SEQ ID NO: 10, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO: 11 and a heavy chain CDR3 having the amino acid sequence of SEQ ID NO: 12, and SEQ ID NO: 14 It was designed to include a light chain variable region comprising a light chain CDR1 having an amino acid sequence, a light chain CDR2 having an amino acid sequence of SEQ ID NO: 15, and a light chain CDR3 having an amino acid sequence of SEQ ID NO: 16.
- a heavy chain variable region comprising a heavy chain CDR1 having the amino acid sequence of SEQ ID NO: 18, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO: 19 and a heavy chain CDR3 having the amino acid sequence of SEQ ID NO: 20, and SEQ ID NO: 22 It was designed to include a light chain variable region comprising a light chain CDR1 having an amino acid sequence, a light chain CDR2 having an amino acid sequence of SEQ ID NO: 23, and a light chain CDR3 having an amino acid sequence of SEQ ID NO: 24.
- CD5 ScFv order #One SEQ ID NO: 35
- Chimeric antigen receptor to be introduced into natural killer cells by using the extracellular domain comprising the four scFvs designed as described above as antigen-binding sites, and using the CAR region of the sequence shown in Table 2 below; CAR) was designed.
- the extracellular domain containing the above four scFvs as antigen-binding sites, and CD28 as a transmembrane domain were linked to Myc and hinge domains, and CD3-zeta and CD3-zeta as an intracellular signaling domain to the transmembrane domain.
- the chimeric antigen receptor of the present invention was designed to have an intracellular signaling domain of a chimeric antigen receptor classified as a so-called third-generation CAR by adding and linking CD28 DAP10 as a costimulatory molecule ('CD5#1-CAR', respectively) ', 'CD5#4-CAR', 'CD5#11-CAR' and 'CD5#14-CAR', which are collectively referred to as 'CD5-CAR'). Then, the nucleotide sequence of the gene construct encoding it was inserted into a lenti-viral vector (Clontech, 632155) (FIG. 1).
- the lenti-viral vector prepared in Example 1-2 was transformed into HEK293T cells together with a viral packaging vector (PMDLg/RRE, RSV/REV, VSVG), and the lentivirus expressing CD5-CAR therefrom. got The lentivirus was concentrated using an ultra-high speed centrifuge, and the concentrated lentivirus was infected with HEK293T cells, and the amount of the Myc epitope of CD5-CAR was checked by flow cytometry to Infection Unit. was calculated.
- a viral packaging vector PMDLg/RRE, RSV/REV, VSVG
- the number of natural killer cells and the amount of lentivirus were calculated so that the multiplicity of infection (MOI) was 30, and the lentivirus expressing CD5-CAR was applied to the natural killer cells (NK92 cells) by spinoculation method (360g, 90min). , RT). After culturing the infected natural killer cells as described above for 5 hours at 37° C., 5% CO 2 condition, they are replaced with fresh culture medium, and after 3 days, puromycin at a concentration of 3ug/ml for selection of properly infected natural killer cells. (puromycin) was treated to continue the culture.
- uninfected natural killer cells were also treated with puromycin, and culture was continued using a puromycin-treated medium until all the natural killer cells in the control were killed by puromycin.
- the infected natural killer cells were selected, and the selected natural killer cells were re-cultured in a medium without puromycin to proliferate or expand.
- the proliferation or expansion of the selected natural killer cells includes Alpha-MEM containing 12.5% fetal bovine serum, 12.5% horse serum, 0.2 mM inositol, 0.1 mM 2-mercaptoethanol, 0.02 mM folic acid, and 200 U/ml recombinant IL- 2 was used.
- Natural killer cells expressing CD5#1-CAR, CD5#4-CAR, CD5#11-CAR and CD5#14-CAR produced and selected as described above ('CD5#1-CAR-NK cells', ' CD5#4-CAR-NK cells', 'CD5#11-CAR-NK cells' and 'CD5#14-CAR-NK cells', which are collectively referred to as 'CD5-CAR-NK cells');
- the expression of CD5-CAR was checked by treating the anti-myc antibody (CST; 9B11) that specifically binds to myc of CD5-CAR (4°C, 30 min in the dark), and confirming the expression of Myc through flow cytometry. Confirmed. In this case, as a control, the original natural killer cells that do not express CD5-CAR were used.
- CD5-CAR was properly expressed in all four types of CD5-CAR-NK cells compared to the control group.
- the cytotoxicity was confirmed by the calcein AM assay. Specifically, after reacting MOLT4 cells and U937 cells with calcein-AM (life technologies; C1430) at a concentration of 5ug/ml (37°C, 5% CO2, 1 hour in the dark), the cells were stained with calcein.
- MOLT4 cells and U937 cells were treated with each of the four CD5-CAR-NK cells in a ratio of 2:1, 1:1, 0.5:1 (natural killer cells: cancer cells), and 200ul of RPMI1640 (10% FBS) ) after the reaction (at 37° C., 5% CO 2 for 2 hours), 100 ul of the supernatant was taken and the amount of calcein present in the supernatant was checked, and the cytotoxicity according to each condition was calculated in the following way.
- Cytotoxicity (%) (calcein release value-spontaneous value according to conditions) / (maximum value-spontaneous value) x 100
- an empty lenti-viral vector that does not contain the gene construct encoding the CD5-CAR of the present invention or a gene construct in which the extracellular domain has been removed from the CD5-CAR of the present invention was included.
- the lenti-viral vector was introduced into natural killer cells in the same manner as in Example [1-3], and natural killer cells obtained through the process of selection with puromycin were used, and these were used as 'PURO NK cells' and 'dEcto', respectively. -NK cells.
- CD5#11-CAR-NK cells two types confirmed to have the best cytotoxicity among the four types of CD5-CAR-NK cells as described above were selected.
- CD5#11-CAR-NK cells two types confirmed to have the best cytotoxicity among the four types of CD5-CAR-NK cells as described above were selected.
- CD5#14-CAR-NK cells two types confirmed to have the best cytotoxicity among the four types of CD5-CAR-NK cells as described above were selected
- CD5-CAR-NK cells two types confirmed to have the best cytotoxicity among the four types of CD5-CAR-NK cells as described above were selected.
- CD5-CAR-NK cells two types confirmed to have the best cytotoxicity among the four types of CD5-CAR-NK cells as described above were selected
- CD5-CAR-NK cells two types confirmed to have the best cytotoxicity among the four types of CD5-CAR-NK cells as described above were selected
- CD5-CAR-NK cells two types confirmed to have the best cyto
- both CD5-CAR-NK cells were significantly higher than the control group (PURO NK cells or dEcto-NK cells) for CD5-expressing CCRF-CEM cells and Jurkat cells. While it was confirmed that high cytotoxicity was shown, it was confirmed that neither the control nor the two CD5-CAR-NK cells showed little cytotoxicity against Daudi cells that do not express CD5.
- cytokines and granules were confirmed for the four types of CD5-CAR-NK cells. Specifically, MOLT4 cells and U937 cells were treated with Puro NK cells, dEcto-NK cells, or each of the four CD5-CAR-NK cells prepared in Example 1-3 at a 1:1 ratio to receive RPMI1640 (10% FBS). After the reaction at (37° C., 5% CO 2 condition for 12 hours), the supernatant was collected and IFN- ⁇ , a cytokine present in the supernatant, was confirmed through ELISA. At this time, the amount of cytokines secreted from Puro NK cells, dEcto-NK cells and CD5-CAR-NK cells alone was used as a control.
- MOLT4 cells and U937 cells were treated with Puro NK cells, dEcto-NK cells, or each of the four CD5-CAR-NK cells prepared in Example 1-3 at a 1:1 ratio in RPMI1640 (10% FBS). After reaction (4 hours at 37° C., 5% CO 2 condition), anti-CD56 antibody was treated and stained to select natural killer cells, and Puro NK cells, dEcto-NK cells and The expression level of CD107a in the four types of CD5-CAR-NK cells was analyzed.
- CD107a expression was significantly improved only in CD5-CAR-NK cells treated with CD5-expressing MOLT4 cells, as in the case of INF- ⁇ .
- NMC from umbilical cord blood using the Ficoll-Paque ® Gradient method. (mononuclear cells) were isolated. Specifically, the umbilical cord blood was carefully placed on the ficoll and centrifuged for 30 minutes at 2000 rpm at room temperature, and then a buffy coat (enriched MNC fraction) containing leukocytes and platelets was separated. The fraction separated as described above was treated with 1X ACK (Ammonium-Chloride-Potassium) lysis buffer at 37° C. for 10 minutes to break up the remaining red blood cells and only pure MNCs were separated.
- 1X ACK Ammonium-Chloride-Potassium
- the CD5#11-CAR-NK cells and CD5#14-CAR-NK cells prepared in Example 1-3 were each in a ratio of 1:1 (Natural Killer Cells: MNC) cytotoxicity of CD5-CAR-NK cells was confirmed in the same manner as in Example [2-1].
- both CD5#11-CAR-NK cells and CD5#14-CAR-NK cells showed reduced cytotoxicity to MNC compared to MOLT4, a cancer cell expressing CD5. Confirmed.
- each of the CD5#11-CAR-NK cells and CD5#14-CAR-NK cells prepared in Example 1-3 was isolated as single cells in a 96-well plate. . Then, the cells proliferating at a similar rate were repeatedly selected and propagated in the order of a 48-well plate, a 24-well plate, a 6-well plate, and a 25T flask.
- CD5-CAR was confirmed in each of the single cells of the CD5#11-CAR-NK cells and the CD5#14-CAR-NK cells isolated as described above, and based on this, the CD5-CAR Cell lines with different expression levels were constructed (Fig. 7a).
- CD5#11-CAR-NK cells and CD5#14-CAR-NK cells constructed as described above were targeted for MOLT4, a cancer cell line expressing CD5, and MNCs isolated in Example [2-2].
- the cytotoxicity of individual single cell lines of CD5-CAR-NK cells was evaluated in the same manner as in Example [2-1] by treating single cell lines of each at a ratio of 1:1 (natural killer cells: cancer cells or MNC). Confirmed.
- CD5-CAR-NK cells among the two types of CD5-CAR-NK cells, individual single cell lines of CD5#11-CAR-NK cells, which show lower cytotoxicity to normal T cells, were CD5-expressing cancer cells.
- a single cell line showing high cytotoxicity to MOLT4 but low cytotoxicity to MNC containing normal T cells was selected.
- CD5-CAR-NK cells of the present invention were prepared using primary natural killer cells instead of NK92 cells, they exhibit excellent activity as confirmed in Examples [2-1] to [2-3]. I checked if it can.
- the mRNA constructs of CD5#11-CAR and CD5#14-CAR were designed and manufactured by combining the UTR of mRNA to improve protein expression and mRNA safety.
- the base sequence of the same mRNA construct was inserted into a lenti-viral vector (Clontech, 632155).
- the mRNA synthesis kit EZTM High Yield In Vitro Transcription kit
- the mRNA of CD5-CAR having the structure shown in FIG. 8 was synthesized using the gene construct as a template.
- CD5-CAR The mRNA of CD5-CAR synthesized as described above was introduced into primary NK cells by electroporation, and after 7 hours, an anti-Myc antibody (CST; 9B11) that specifically binds to Myc of CD5-CAR was prepared. After treatment (4°C, 30 minutes in the dark), the expression of Myc was confirmed by flow cytometry. As a result, as shown in FIG. 9 , CD5-CAR in primary natural killer cells It was confirmed that the CAR was properly expressed.
- CST anti-Myc antibody
- Example [2-2] two types of CD5- CAR-NK cells were treated at a ratio of 0.5:1 and 1:1, respectively (primary natural killer cells: cancer cells), and in the same manner as in Example [2-1], primary natural killer cell-based CD5-CAR- Cytotoxicity of NK cells was confirmed.
- the CD5-CAR-NK cells based on the two primary natural killer cells were all control (PURO NK cells) for MOLT4 cells and CCRF-CEM cells, which are cancer cells expressing CD5. or dEcto-NK cells), as well as exhibiting much higher cytotoxicity, and this cytotoxicity was confirmed to be concentration-dependent on the treated CD5-CAR-NK cells. On the other hand, it was confirmed to show a more reduced cytotoxicity to MNCs containing normal T cells expressing CD5.
- the CD5-CAR-NK cells of the present invention exhibited toxic high cytotoxicity to CD5-expressing cancer cells.
- the expression of ligands involved in the activation of natural killer cells in MOLT4, CCRF-CEM, and Jurkat which are cancer cells expressing MNC and CD5 isolated in Example [2-2], which are normal cells, were examined. Confirmed. Each of the cells was treated with an antibody that specifically binds to each ligand, and the expression level of the corresponding ligand was analyzed by flow cytometry.
- B7-H6 was significantly highly expressed in all three types of cancer cells, and HLA class1, an inhibitory ligand, was expressed in normal cells. was found to be highly expressed.
- CD3 as a marker for T cells
- CD34 as a marker for hematopoietic stem cells (HSC)
- markers for myeloid cells As a result of treatment with an antibody that specifically binds to CD33 and CD56, a marker for natural killer cells, respectively, and measuring the expression level of B7-H6 for each type of leukocyte by flow counting method, as shown in FIG. 11b , most It was confirmed that B7-H6 was not expressed in normal leukocytes of
- siRNA having a sequence complementary to the gene of B7-H6 was introduced into MOLT4 cells and Jurkat cells, which are cancer cell lines expressing CD5, to temporarily knock-down the expression of B7-H6. . Then, for the cancer cells with reduced expression of B7-H6 as described above, CD5#11-CAR-NK cells were treated at a ratio of 1:1 (natural killer cells: cancer cells), respectively, and 2-1], the cytotoxicity of CD5#11-CAR-NK cells was confirmed.
- CD5#11-CARNK cells were each in a 1:1 ratio (natural killer cells: cancer cells or MNCs). ), and the expression levels of B7-H6 and CD5 in live MOLT4 cells and MNCs were measured every 2 hours by flow cytometry.
- CD5-CAR-NK cells of the present invention not only exhibit concentration-dependently enhanced cytotoxicity against CD5-expressing cancer cells, but also increase IFN- ⁇ secretion and degranulation. It can be seen that the CD5-CAR-NK cells of the present invention respond specifically to cancer cells expressing CD5.
- CD5 is expressed in most T cell malignancies, it is also expressed in normal T cells, and it has been reported that all CD5-CARs developed to date have adverse effects on normal T cells.
- CD5-CAR-NK cells of the present invention it was confirmed that they showed a more reduced cytotoxicity to MNCs isolated from umbilical cord blood, and in particular, CD5#11-CAR-NK cells were CD5#14-CAR-NK cells. It was confirmed to exhibit a lower cytotoxicity compared to cells.
- the difference between the CD5#11-CAR-NK cells and the CD5#14-CAR-NK cells as described above is thought to be due to the difference in the structure of the single chain variable fragment, and the heavy chain CDR1 having the amino acid sequence of SEQ ID NO: 18, SEQ ID NO: A heavy chain variable region comprising a heavy chain CDR2 having the amino acid sequence of SEQ ID NO: 19 and a heavy chain CDR3 having the amino acid sequence of SEQ ID NO: 20, a light chain CDR1 having the amino acid sequence of SEQ ID NO: 22, a light chain CDR2 having the amino acid sequence of SEQ ID NO: 23 and a sequence #11 ScFv comprising a light chain variable region comprising a light chain CDR3 having the amino acid sequence of No.
- CD5#11-CAR-NK cells were found to be effective against CD5-expressing cancer cells. It was confirmed that the cytotoxicity against the control group was about 10 times higher than that of the control, whereas the cytotoxicity against the normal cells expressing CD5 was only about 2 times higher than that of the control group. From the above results, it is judged that the CD5#11-CAR-NK cells of the present invention have much higher safety than previously reported CD5-CARs.
- CD5-CAR permanently expressed in NK92 cells
- CD5-CAR-NK cells based on primary NK cells that transiently expressed CD5-CAR by introducing CD5-CAR mRNA into primary NK cells also expressed CD5.
- CD5-CAR-NK cells of the present invention respond differently to CD5-expressing cancer cells and normal cells.
- the expression level of B7-H6 was regulated in cancer cells expressing CD5, it was confirmed that the cytotoxicity of the CD5-CAR-NK cells of the present invention changed according to the expression level of B7-H6, and from this, it was confirmed that B7 Since -H6 acts as a major factor in the activity of the CD5-CAR-NK cells of the present invention and is relatively highly expressed in CD5-expressing cancer cells, the CD5-CAR-NK cells of the present invention are more effective in cancer cells than normal cells. It can be seen that it is the first to react.
- the cytotoxicity to CD5-expressing cancer cells and normal cells can be completely differentiated due to the difference in CD5-CAR activity due to the difference in the CDR sequence of the antibody against CD5.
- Using a single cell line with cytotoxicity it is expected that it will be possible to develop a new therapeutic agent for T-cell hematologic malignancies that show high anticancer effects on cancer cells and have low responsiveness to normal cells.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
CD5 ScFv | 서열 |
#1 (서열번호 35) |
MKYLLPTAAAGLLLLAAQPAMAEVQLVESGGGLVQPGGSLRLSCAASGFTFSDYGMHWVRQAPGKGLEWVSAISGSGSSTHYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKGSSSVYSEAMDLWGQGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSASVGDRVTITCRASQDISSYLNWYQQKPGKAPKLLIYATSNLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYTYPWTFGQGTKVEIKASTGPGGQHHHHHHGAWSHPQFEK CDR1-VH (서열번호 2): DYGMH CDR2-VH (서열번호 3): AISGSGSSTHYADSVKG CDR3-VH (서열번호 4): GSSSVYSEAMDL CDR1-VL (서열번호 6): RASQDISSYLN CDR2-VL (서열번호 7): ATSNLQS CDR3-VL (서열번호 8): QQSYTYPWT |
#4 (서열번호 36) |
MKYLLPTAAAGLLLLAAQPAMAEVQLVESGGGLVQPGGSLRLSCAASGFTFSDYAMSWVRQAPGKGLEWVSAISQSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDLASVYGAAFDVWGQGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSASVGDRVTITCRASQTIASYLNWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSFPWTFGQGTKVEIKASTGPGGQHHHHHHGAWSHPQFEK CDR1-VH (서열번호 10): DYAMS CDR2-VH (서열번호 11): AISQSGGSTYYADSVKG CDR3-VH (서열번호 12): DLASVYGAAFDV CDR1-VL (서열번호 14): RASQTIASYLN CDR2-VL (서열번호 15): AASTLQS CDR3-VL (서열번호 16): QQSYSFPWT |
#11 (서열번호 37) |
MKYLLPTAAAGLLLLAAQPAMAEVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISSSGGSKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKRSYAGEYFDHWGQGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSASVGDRVTITCRASQSISNWLNWYQQKPGKAPKLLIYDASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSFPWTFGQGTKVEIKASTGPGGQHHHHHHGAWSHPQFEK CDR1-VH (서열번호 18): SYAMS CDR2-VH (서열번호 19): AISSSGGSKYYADSVKG CDR3-VH (서열번호 20): RSYAGEYFDH CDR1-VL (서열번호 22): RASQSISNWLN CDR2-VL (서열번호 23): DASSLQS CDR3-VL (서열번호 24): QQSYSFPWT |
#14 (서열번호 38) |
MKYLLPTAAAGLLLLAAQPAMAEVQLVESGGGLVQPGGSLRLSCAASGFTFSDYAMHWVRQAPGKGLEWVSAISSSGSYTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKGSYYGYYFDIWGQGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSASVGDRVTITCRASQSISNDLNWYQQKPGKAPKLLIYDTSRLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSFPWTFGQGTKVEIKASTGPGGQHHHHHHGAWSHPQFEK CDR1-VH (서열번호 26): DYAMH CDR2-VH (서열번호 27): AISSSGSYTYYADSVKG CDR3-VH (서열번호 28): GSYYGYYFDI CDR1-VL (서열번호 30): RASQSISNDLN CDR2-VL (서열번호 31): DTSRLQS CDR3-VL (서열번호 32): QQSYSFPWT |
CAR 영역 | 서열 |
Signal peptide (서열번호 43) |
ACCATGGCCTTACCAGTGACCGCCTTGCTCCTGCCGCTGGCCTTACTGCTCCACGCCGCCAGGCCGGC |
Myc (서열번호 44) |
GCGAACAAAAACTCATCTCAGAAGAGGATCTG |
Hinge (서열번호 45) |
GGGGTCACCGTCTCTTCAGCGCTGAGCAACTCCATCATGTACTTCAGCCACTTCGTGCCGGTCTTCCTGCCAGCGAAGCCCACCACGACGCCAGCGCCGCGACCACCAACACCGGCGCCCACCATCGCGTCGCAGCCCCTGTCCCTGCGCCCAGAGGCATGCCGGCCAGCGGCGGGGGGCGCAGTGCACACGAGGGGGCTGGAT |
Transmembrane (서열번호 46) |
GTGAAAGGGAAACACCTTTGTCCAAGTCCCCTATTTCCCGGACCTTCTAAGCCCTTTTGGGTGCTGGTGGTGGTTGGTGGAGTCCTGGCTTGCTATAGCTTGCTAGTAACAGTGGCCTTTATTATTTTCTGGGTGAGGAGTAAGAGGAGCAGGCTCCTGCACAGTGACTACATGAACATGACTCCCCGCCGCCCCGGGCCCACCCGCAAGCATTACCAGCCCTATGCCCCACCACGCGACTTCGCAGCCTAT |
DAP10 (서열번호 47) |
CTGTGCGCACGCCCACGCCGCAGCCCCGCCCAAGAAGATGGCAAAGTCTACATCAACATGCCAGGCAGGGGC |
CD3ζ (서열번호 48) |
TAGAGTGAAGTTCAGCAGGAGCGCAGACGCCCCCGCGTACCAGCAGGGCCAGAACCAGCTCTATAACGAGCTCAATCTAGGACGAAGAGAGGAGTACGATGTTTTGGACAAGAGACGTGGCCGGGACCCTGAGATGGGGGGAAAGCCGAGAAGGAAGAACCCTCAGGAAGGCCTGTACAATGAACTGCAGAAAGATAAGATGGCGGAGGCCTACAGTGAGATTGGGATGAAAGGCGAGCGCCGGAGGGGCAAGGGGCACGATGGCCTTTACCAGGGTCTCAGTACAGCCACCAAGGACACCTACGACGCCCTTCACATGCAGGCCCTGCCCCCTCGCTAA |
Claims (14)
- i) 서열번호 2, 서열번호 10, 서열번호 18 및 서열번호 26으로 이루어지는 군에서 선택되는 어느 하나의 아미노산 서열을 갖는 중쇄 CDR1, ii) 서열번호 3, 서열번호 11, 서열번호 19 및 서열번호 27로 이루어지는 군에서 선택되는 어느 하나의 아미노산 서열을 갖는 중쇄 CDR2 및 iii) 서열번호 4, 서열번호 12, 서열번호 20 및 서열번호 28로 이루어지는 군에서 선택되는 어느 하나의 아미노산 서열을 갖는 중쇄 CDR3를 포함하는 중쇄가변영역; 및iv) 서열번호 6, 서열번호 14, 서열번호 22 및 서열번호 30으로 이루어지는 군에서 선택되는 어느 하나의 아미노산 서열을 갖는 경쇄 CDR1, v) 서열번호 7, 서열번호 15, 서열번호 23 및 서열번호 31로 이루어지는 군에서 선택되는 어느 하나의 아미노산 서열을 갖는 경쇄 CDR2 및 vi) 서열번호 8, 서열번호 16, 서열번호 24 및 서열번호 32로 이루어지는 군에서 선택되는 어느 하나의 아미노산 서열을 갖는 경쇄 CDR3를 포함하는 경쇄가변영역;을 포함하는 CD5에 특이적으로 결합하는, 항체 또는 이의 항원 결합 단편.
- 청구항 1에 있어서,상기 중쇄가변영역은 서열번호 5, 서열번호 13, 서열번호 21 및 서열번호 29로 이루어지는 군에서 선택되는 어느 하나의 아미노산 서열을 갖는 것인, 항체 또는 이의 항원 결합 단편.
- 청구항 1에 있어서,상기 경쇄가변영역은 서열번호 9, 서열번호 17, 서열번호 25 및 서열번호 33으로 이루어지는 군에서 선택되는 어느 하나의 아미노산 서열을 갖는 것인, 항체 또는 이의 항원 결합 단편.
- CD5에 특이적으로 결합하는 항원 결합 부위를 포함하는 세포외 도메인(extracellular binding domain); 막통과 도메인(transmembrane domain); 및 세포내 신호전달 도메인(intracellular signaling domain);을 포함하는, 키메릭 항원 수용체(Chimeric antigen receptor, CAR)로서,상기 CD5에 특이적으로 결합하는 항원 결합 부위는, i) 서열번호 2, 서열번호 10, 서열번호 18 및 서열번호 26으로 이루어지는 군에서 선택되는 어느 하나의 아미노산 서열을 갖는 중쇄 CDR1, ii) 서열번호 3, 서열번호 11, 서열번호 19 및 서열번호 27로 이루어지는 군에서 선택되는 어느 하나의 아미노산 서열을 갖는 중쇄 CDR2 및 iii) 서열번호 4, 서열번호 12, 서열번호 20 및 서열번호 28로 이루어지는 군에서 선택되는 어느 하나의 아미노산 서열을 갖는 중쇄 CDR3를 포함하는 중쇄가변영역과 iv) 서열번호 6, 서열번호 14, 서열번호 22 및 서열번호 30으로 이루어지는 군에서 선택되는 어느 하나의 아미노산 서열을 갖는 경쇄 CDR1, v) 서열번호 7, 서열번호 15, 서열번호 23 및 서열번호 31로 이루어지는 군에서 선택되는 어느 하나의 아미노산 서열을 갖는 경쇄 CDR2 및 vi) 서열번호 8, 서열번호 16, 서열번호 24 및 서열번호 32로 이루어지는 군에서 선택되는 어느 하나의 아미노산 서열을 갖는 경쇄 CDR3를 포함하는 경쇄가변영역을 포함하는 항-CD5 항체의 단일 사슬 가변 단편(single chain variable fragment; scFv)인 것인, 키메릭 항원 수용체.
- 청구항 4에 있어서,상기 CD5에 특이적으로 결합하는 항원 결합 부위는,서열번호 5, 서열번호 13, 서열번호 21 및 서열번호 29로 이루어지는 군에서 선택되는 어느 하나의 아미노산 서열을 갖는 중쇄가변영역을 포함하는 항-CD5 항체의 단일 사슬 가변 단편인 것인, 키메릭 항원 수용체.
- 청구항 4에 있어서,상기 CD5에 특이적으로 결합하는 항원 결합 부위는,서열번호 9, 서열번호 17, 서열번호 25 및 서열번호 33으로 이루어지는 군에서 선택되는 어느 하나의 아미노산 서열을을 갖는 경쇄가변영역을 포함하는 항-CD5 항체의 단일 사슬 가변 단편인 것인, 키메릭 항원 수용체.
- 청구항 4 내지 청구항 6 중 어느 한 항의 키메릭 항원 수용체를 암호화하는 염기서열을 포함하는, 폴리뉴클레오티드.
- 청구항 7의 폴리뉴클레오티드를 포함하는, 발현 벡터.
- 청구항 4 내지 청구항 6 중 어느 한 항의 키메릭 항원 수용체를 표면에 발현하는, 면역세포.
- 청구항 9에 있어서,상기 면역세포는 자연살해 세포(NK cell), T 세포, 자연살해 T 세포(NKT cell), 대식세포 및 수지상세포로 이루어진 군에서 선택되는 적어도 하나인 것인, 면역세포.
- 청구항 9의 면역세포를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물.
- 청구항 11에 있어서,상기 암은 백혈병 또는 림프종을 포함하는 혈액암인 것인, 암의 예방 또는 치료용 약학적 조성물.
- 청구항 12에 있어서,상기 암은 흉선 암종(thymic carcinoma), 비-호지킨 림프종(non-Hodgkin lymphoma), 광범위큰세포림프종(diffuse large cell lymphoma), 소림프구성세포 림프종(small lymphocytic lymphoma), T-세포 종양(T-cell neoplasma), 말초 T-세포 림프종(peripheral T-cell lymphoma), 외투세포림프종(mantle cell lymphoma), T-세포 급성림프구성백혈병(T-cell acute lymphobalstic lymphoma) 및 만성림프성백혈병(chronic lymphoblastic lymphoma)로 이루어진 군에서 선택되는 적어도 하나인 것인, 암의 예방 또는 치료용 약학적 조성물.
- 청구항 11에 있어서,항암 화학요법제를 추가로 포함하는 것인, 암의 예방 또는 치료용 약학적 조성물.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP22796130.7A EP4332118A1 (en) | 2021-04-29 | 2022-04-27 | Novel anti-cd5 chimeric antigen receptor and immune cell expressing same |
JP2023566973A JP2024516263A (ja) | 2021-04-29 | 2022-04-27 | 新規な抗cd5キメラ抗原受容体及びそれを発現する免疫細胞 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20210055886 | 2021-04-29 | ||
KR10-2021-0055886 | 2021-04-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022231298A1 true WO2022231298A1 (ko) | 2022-11-03 |
Family
ID=83847038
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2022/006009 WO2022231298A1 (ko) | 2021-04-29 | 2022-04-27 | 신규한 항-cd5 키메릭 항원 수용체 및 이를 발현하는 면역세포 |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP4332118A1 (ko) |
JP (1) | JP2024516263A (ko) |
KR (1) | KR20220148745A (ko) |
WO (1) | WO2022231298A1 (ko) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110250203A1 (en) * | 2008-08-29 | 2011-10-13 | Symphogen A/S | Anti-cd5 antibodies |
KR20180002604A (ko) | 2015-02-27 | 2018-01-08 | 아이셀 진 테라퓨틱스 엘엘씨 | 혈액 악성종양을 표적으로 하는 키메라 항원 수용체(car), 조성물 및 이의 용도 |
WO2020023561A1 (en) * | 2018-07-23 | 2020-01-30 | Magenta Therapeutics, Inc. | Use of anti-cd5 antibody drug conjugate (adc) in allogeneic cell therapy |
KR102122546B1 (ko) | 2017-01-05 | 2020-06-15 | 한국생명공학연구원 | 항-코티닌 키메릭 항원 수용체를 발현하는 자연살해 세포 |
US20200405811A1 (en) * | 2015-04-23 | 2020-12-31 | Baylor College Of Medicine | Cd5 chimeric antigen receptor for adoptive t cell therapy |
-
2022
- 2022-04-27 EP EP22796130.7A patent/EP4332118A1/en active Pending
- 2022-04-27 JP JP2023566973A patent/JP2024516263A/ja active Pending
- 2022-04-27 KR KR1020220052018A patent/KR20220148745A/ko unknown
- 2022-04-27 WO PCT/KR2022/006009 patent/WO2022231298A1/ko active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110250203A1 (en) * | 2008-08-29 | 2011-10-13 | Symphogen A/S | Anti-cd5 antibodies |
KR20180002604A (ko) | 2015-02-27 | 2018-01-08 | 아이셀 진 테라퓨틱스 엘엘씨 | 혈액 악성종양을 표적으로 하는 키메라 항원 수용체(car), 조성물 및 이의 용도 |
US20200405811A1 (en) * | 2015-04-23 | 2020-12-31 | Baylor College Of Medicine | Cd5 chimeric antigen receptor for adoptive t cell therapy |
KR102122546B1 (ko) | 2017-01-05 | 2020-06-15 | 한국생명공학연구원 | 항-코티닌 키메릭 항원 수용체를 발현하는 자연살해 세포 |
WO2020023561A1 (en) * | 2018-07-23 | 2020-01-30 | Magenta Therapeutics, Inc. | Use of anti-cd5 antibody drug conjugate (adc) in allogeneic cell therapy |
Non-Patent Citations (4)
Title |
---|
APPL ENVIRON MICROBIOL, vol. 64, 1998, pages 3932 - 3938 |
MOL GEN GENET, vol. 250, 1996, pages 734 - 741 |
WADA MASAYUKI; ZHANG HONGYU; FANG LIU; FENG JIA; TSE CHARLOTTE OLIVIA; ZHANG WENLI; CHEN QI; SHA SHA; CAO YUANZHEN; CHEN KEVIN H.;: "Characterization of an Anti-CD5 Directed CAR T-Cell against T-Cell Malignancies", STEM CELL REVIEWS AND REPORTS, vol. 16, no. 2, 1 February 2020 (2020-02-01), New York , pages 369 - 384, XP037090843, ISSN: 2629-3269, DOI: 10.1007/s12015-019-09937-9 * |
YANOFSKY, C, J BACTERIOL, vol. 158, 1984, pages 1018 - 1024 |
Also Published As
Publication number | Publication date |
---|---|
EP4332118A1 (en) | 2024-03-06 |
KR20220148745A (ko) | 2022-11-07 |
JP2024516263A (ja) | 2024-04-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2002512502A (ja) | 癌細胞の標的細胞溶解 | |
WO2021256724A1 (ko) | Bcma를 표적으로 하는 키메라 항원 수용체 및 이의 용도 | |
US20240082306A1 (en) | Novel chimeric antigen receptor and use thereof | |
WO2020005003A1 (ko) | Lag-3에 특이적으로 결합하는 단클론항체 및 이의 용도 | |
WO2022030730A1 (ko) | 메소텔린에 특이적으로 결합하는 항-메소텔린 키메릭 항원 수용체 | |
EP4194472A1 (en) | Chimeric antigen receptor comprising novel co-stimulatory domain and use thereof | |
WO2022218226A1 (zh) | 工程化免疫细胞及其用途 | |
WO2024049161A1 (ko) | 신규한 항-pd-l1 키메릭 항원 수용체 및 이를 발현하는 면역세포 | |
WO2021210939A1 (ko) | 항-her2 어피바디 및 이를 스위치 분자로 이용하는 스위처블 키메라 항원 수용체 | |
WO2021060914A1 (ko) | 항-클라우딘-3 키메라 항원 수용체 | |
WO2023003404A1 (ko) | 신규한 키메릭 항원 수용체 및 이를 발현하는 면역세포 | |
WO2022231298A1 (ko) | 신규한 항-cd5 키메릭 항원 수용체 및 이를 발현하는 면역세포 | |
WO2022250440A1 (ko) | Erbb3 특이적인 키메라 항원 수용체 및 이를 발현하는 면역세포 치료제 | |
WO2021235697A1 (ko) | Cd22에 특이적인 항체 및 이의 용도 | |
WO2023014182A1 (ko) | 신규한 항-epha2 키메릭 항원 수용체 및 이를 발현하는 면역세포 | |
CN115521917A (zh) | 工程化免疫细胞及其用途 | |
CN115725503A (zh) | 工程化免疫细胞 | |
WO2023027471A1 (ko) | 기능이 강화된 신규 키메라 항원 수용체(car) | |
US20240216428A1 (en) | Novel Anti-CD5 Chimeric Antigen Receptor and Immune Cell Expressing Same | |
WO2018128486A1 (ko) | Ceacam6에 특이적으로 결합하는 항-ceacam6 키메릭 항원 수용체 | |
WO2021060932A1 (ko) | 항-c-met 항체 또는 그의 항원 결합 단편을 포함하는 키메라 항원 수용체, 및 이의 용도 | |
WO2022250450A1 (ko) | 항 메소텔린 scFv를 포함하는 키메릭 항원 수용체 및 이의 용도 | |
WO2022215919A1 (ko) | Cd47에 특이적으로 결합하는 키메릭 항원 수용체 및 이의 용도 | |
WO2023068584A1 (ko) | Cd138에 특이적으로 결합하는 키메릭 항원 수용체 및 이의 용도 | |
WO2022186682A1 (ko) | Rank 리간드(rank ligand)에 특이적으로 결합하는 키메릭 항원 수용체 및 이의 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22796130 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18288815 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023566973 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022796130 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022796130 Country of ref document: EP Effective date: 20231129 |